Executive interview – Silence Therapeutics

Published on 18 July 2019
 

In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.

Share this with friends and colleagues

You may also be interested in these

Executive interview – Cantargia

Healthcare
29 January 2020

Bitesize briefing – Alaska’s North Slope

Oil & gas
28 January 2020

Executive interview – Ilika

Industrials
24 January 2020
SureserveETV23012020_thumb.jpg

Executive interview – Sureserve

Industrials
23 January 2020

Cookies

This site uses cookies: Find out more.